haemophilia A

News

NHS broadens access to haemophilia A drug Hemlibra

More people living with haemophilia A will be able to get access to Roche/Chugai's Hemlibra thanks to a commissioning agreement with NHS England.

News

Roche's Hemlibra follow-up set for phase 3 in haemophilia A

Roche has positive data with its follow-up to haemophilia A blockbuster Hemlibra, but a rival drug from Novo Nordisk is looming.

News

UK haemophilia A patients get once-weekly treatment option

A long-acting Factor VIII replacement therapy for haemophilia A from Sobi and Sanofi has been recommended for use by the NHS.

News

Pfizer ducks out of Sangamo haemophilia A alliance

Sangamo is "surprised and disappointed" by Pfizer's decision to return rights to its gene therapy for haemophilia A after positive phase 3 results.

News

Pfizer bags EU okay for haemophilia drug Hympavzi

Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU

News

Novo Nordisk closes on EU okay for haemophilia antibody

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia.

NHS broadens access to haemophilia A drug Hemlibra

Roche's Hemlibra follow-up set for phase 3 in haemophilia A

UK haemophilia A patients get once-weekly treatment option

Pfizer ducks out of Sangamo haemophilia A alliance

Pfizer bags EU okay for haemophilia drug Hympavzi

Novo Nordisk closes on EU okay for haemophilia antibody

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

haemophilia A

Editor's Picks